Mu kafukufuku wofalitsidwa mu magazini ya November ya Journal of Personalized Medicine , ofufuza adafufuza zomwe zimachitika pamene opioid wamba monga hydrocodone, oxycodone, codeine, ndi tramadol, omwe amafunikira enzyme inayake kuti athetse ululu, amatengedwa ndi mankhwala ena omwe amafunikira. enzyme yemweyo. Anthu omwe amamwa osachepera amodzi mwa ma opioid awa komanso mankhwala ena amodzi omwe amapikisana ndi enzymeyi anali ndi ndalama zambiri zakuchipatala pachaka komanso kuchuluka kwa ma opioid tsiku lililonse kuposa anthu omwe amamwa imodzi mwama opioidwa koma osagwiritsa ntchito mankhwala osokoneza bongo. Kuonjezera apo, ofufuza adapeza kuti anthu omwe amamwa mankhwala opioid osachepera limodzi ndi mankhwala amodzi omwe amamwa mowa nthawi zambiri amakhala ndi chiopsezo chachikulu cha zochitika zina za mankhwala osokoneza bongo, kutengera TRHC's MedWise Science, yomwe imawona mndandanda wa mankhwala onse a wodwala pamene akuyesa zokhudzana ndi mankhwala. mavuto.
"Ndi Sayansi ya MedWise, tikhoza kudziwa yemwe ali ndi chiopsezo chachikulu cha zotsatira zoipa chifukwa cha kuyanjana kwa mankhwala," adatero Pulezidenti wa TRHC ndi CEO Calvin H. Knowlton, PhD. "Kusintha machitidwe amakono kuti mupewe kuyanjana kwa mankhwala kungapangitse chitetezo cha mankhwala, zomwe zingathe kupititsa patsogolo mphamvu ya opioid kwa odwala ena ndikuchepetsa zotsatira zoipa za odwala ndi ndalama zomwe zimayendera."
Kafukufuku wosiyana mu Journal of Palliative Medicine adagwiritsa ntchito MedWise Science ndi zida zake zothandizira zisankho zachipatala kuti awunike zambiri zamtundu wokhudzana ndi kagayidwe ka opioid. Kafukufukuyu akuwonetsa kuti azachipatala omwe amagwiritsa ntchito deta ya pharmacogenomic angathandize asing'anga kukulitsa chitetezo chamankhwala. Malinga ndi kafukufukuyu, 85% ya asing'anga adawonetsa kuti zida zothandizira zisankho zidathandizira chisamaliro cha odwala omwe adamwa opioids.
"Kusanthula kwa majini kumabweretsa umunthu komanso kulondola pakati pa chitetezo chamankhwala," adatero Jacques Turgeon, BPharm, PhD, TRHC Chief Scientific Officer ndi CEO wa Precision Pharmacotherapy Research and Development Institute. "Kuthandizira zisankho zachipatala kudzera ku MedWise Science kumathandizira asing'anga kuphwanya zomwe zabadwa ndikuwapatsa malangizo othandiza kuti apewe zovuta zamankhwala."
ZOMWE MUNGACHITE PA NKHANIYI:
- People who took at least one of these opioids and at least one other drug that competes for that enzyme had higher average yearly medical expenses and a greater average daily opioid intake than people who took at least one of these opioids but no interacting drugs.
- Additionally, researchers found that individuals who took at least one of these opioids and at least one interacting drug generally had a greater risk of other adverse drug events, based on TRHC’s MedWise Science, which considers a patient’s entire medication list when assessing for drug-related problems.
- In a study published in the November issue of the Journal of Personalized Medicine, researchers examined what happens when common opioids such as hydrocodone, oxycodone, codeine, and tramadol, which need a particular enzyme to activate pain relief, are taken with other medications that require the same enzyme.
